Lenmeldy is a one-time, individualized single-dose infusion made from a patient’s own hematopoietic stem cells, which have been genetically modified to include functional copies of the ARSA gene that codes for the arylsulfatase A enzyme. It is indicated for presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile MLD.
The priority-review orphan drug approval was based on data from 37 children who received Lenmeldy. Compared with untreated children, Lenmeldy significantly reduced the risk for severe motor impairment or death.
All children with presymptomatic late infantile MLD treated with Lenmeldy were alive at 6 years of age versus only 58 percent of untreated children. Seven in 10 treated children (71 percent) were able to walk without assistance at 5 years of age, and 85 percent had normal language and performance IQ scores.
Children with presymptomatic early juvenile and early symptomatic early juvenile MLD showed slowing of motor and/or cognitive disease with Lenmeldy.
“MLD is a devastating disease that profoundly affects the quality of life of patients and their families. Advancements in treatment options offer hope for improved outcomes and the potential to positively influence the trajectory of disease progression,” Nicole Verdun, M.D., director of the Office of Therapeutic Products at the FDA, said in a statement.
“This approval represents important progress in the advancement and availability of effective treatments, including gene therapies, for rare diseases.”
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Groundbreaking Intravenous Gene Therapy Offers New Hope for Metachromatic Leukodystrophy Patients
A recent study conducted by researchers from the TIDU GENOV at the Institut du Cerveau in Paris, France, presents promising results for the treatment of Metachromatic Leukodystrophy (MLD), a severe neurodegenerative disease. Led by Emilie Audouard with key...
Astellas’ Friedreich’s ataxia gene therapy cleared for clinical study after earlier version stumbled
After hitting a speed bump in its first attempt at developing a gene therapy for Friedreich’s ataxia, Astellas is ready to put a new version in the clinic. On Thursday, the Japanese drugmaker announced the FDA has cleared its IND for ASP2016. The company is hoping to...
Autolomous and BioCentriq Partner to Speed Up Cell Therapy Delivery
Collaboration leverages cutting-edge digital platform to streamline development and manufacturing activities and speed patient access to life-changing treatmentsLONDON and NEWARK, N.J., April 24, 2024 /PRNewswire/ -- Autolomous, the market-leading developer of...
Study reviews the role of a ribonucleic acid ‘MALAT1’ in hematological malignancies
Recent studies have shown that an abnormally high expression of MALAT1 in blood cancer cells could aid the chemotherapeutic resistance development through multiple intermolecular interactions. Although researchers first identified the role of MALAT1 in patients with...
Related Services
Plasmids GMP Services
AAV GMP Services
